The ETS1 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from Raji B lymphoblastoid cells, with targeted disruption of the ETS1 gene. This heterogeneous loss-of-function model enables pooled functional studies and eliminates clonal bias inherent in monoclonal lines, facilitating investigation of ETS1??s roles in B-cell biology and lymphomagenesis.
Raji cells are an EBV-positive human B lymphoblastoid line from a Burkitt lymphoma patient, widely used as a model for mature B-cell malignancies. Their constitutive activation of BCR and NF-??B signaling, coupled with rapid proliferation, makes them ideal for studying lymphomagenesis, drug screening, and signal transduction. The EBV-transformed background further provides a relevant context for examining oncogenic cooperativity with ETS1.
ETS1 is a transcription factor that integrates upstream signals from the MAPK/ERK and BCR pathways. It is activated by ERK1/2 (MAPK3/MAPK1) phosphorylation and modulated by kinases SYK, BTK, and PKC, as well as Ca2+/calcineurin/NFAT and IL-2 receptor cascades. ETS1 directly regulates key target genes such as CDKN1A (p21), CCND1 (cyclin D1), BCL2, MMP3, MMP9, IL2, IL4, and differentiation factors PRDM1 and IRF4. Its transcriptional activity is coordinated through interactions with PAX5, RUNX1, AP-1, NF-??B, and co-repressor complexes containing HDACs, ensuring context-specific gene expression in B cells.
Knocking out ETS1 in Raji cells disrupts BCR-driven proliferative and survival transcriptional programs, providing a model to dissect ETS1-dependent signaling in aggressive B-cell lymphoma. The polyclonal nature of the knockout recapitulates heterogeneous gene disruption, mirroring tumor cell diversity and enabling assessment of variable functional outcomes. This model supports investigation of how ETS1 loss influences lymphomagenesis, treatment resistance, and immune signaling, aiding in target validation.
Applications include Western blotting and RT-qPCR for expression analysis, RNA-seq for transcriptomics, flow cytometry for B-cell markers (CD19, CD20), proliferation (BrdU/EdU) and apoptosis (Annexin V) assays, BCR stimulation with phospho-ERK measurement, luciferase reporters for ETS1 activity, and ChIP-qPCR for target occupancy. These assays enable studies in B-cell development, lymphoma pathogenesis, drug target validation, and CRISPR screening. For further information, please contact Ascent Research.
